Who are Ryanodex and Standard of Care's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ryanodex-and-standard-of-care.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Ryanodex and Standard of Care — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ryanodex and Standard of Care (Ryanodex and Standard of Care) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Ryanodine receptor antagonist. Area: Anesthesiology / Critical Care.

phase 3 Ryanodine receptor antagonist Ryanodine receptor (RyR1) Anesthesiology / Critical Care Small molecule Live · refreshed every 30 min

Target snapshot

Ryanodex and Standard of Care (Ryanodex and Standard of Care) — Eagle Pharmaceuticals, Inc.. Ryanodex is a dantrolene sodium formulation that blocks calcium release from the sarcoplasmic reticulum in skeletal muscle by inhibiting the ryanodine receptor.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ryanodex and Standard of Care TARGET	Ryanodex and Standard of Care	Eagle Pharmaceuticals, Inc.	phase 3	Ryanodine receptor antagonist	Ryanodine receptor (RyR1)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Ryanodine receptor antagonist class)

Eagle Pharmaceuticals, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ryanodex and Standard of Care — Competitive Intelligence Brief. https://druglandscape.com/ci/ryanodex-and-standard-of-care. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab